$3.45 Billion is the total value of Perceptive Advisors's 116 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 68.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FOLD | Buy | AMICUS THERAPEUTICS INC | $285,773,000 | -1.1% | 27,372,917 | +1.8% | 8.29% | -8.3% |
| CERE | Buy | CEREVEL THERAPEUTICS HLDNG I | $184,021,000 | +36.8% | 6,511,727 | +28.0% | 5.34% | +26.8% |
| Buy | AMYLYX PHARMACEUTICALS INC | $154,038,000 | +125.9% | 5,472,033 | +54.6% | 4.47% | +109.3% | |
| Buy | LIANBIOsponsored ads | $115,116,000 | -5.8% | 57,558,451 | +1.8% | 3.34% | -12.7% | |
| Buy | CINCOR PHARMA INC | $108,524,000 | +148.4% | 3,306,649 | +42.6% | 3.15% | +130.3% | |
| BLU | Buy | BELLUS HEALTH INC NEW | $108,209,000 | +111.6% | 10,247,073 | +85.2% | 3.14% | +96.0% |
| RLMD | Buy | RELMADA THERAPEUTICS INC | $88,236,000 | +3729.7% | 2,383,478 | +1864.1% | 2.56% | +3456.9% |
| ALDX | Buy | ALDEYRA THERAPEUTICS INC | $60,609,000 | +53.4% | 11,350,085 | +14.6% | 1.76% | +42.1% |
| INBX | Buy | INHIBRX INC | $51,837,000 | +138.5% | 2,887,860 | +50.8% | 1.50% | +120.9% |
| VRNA | Buy | VERONA PHARMA PLCsponsored ads | $51,583,000 | +322.3% | 5,047,264 | +73.1% | 1.50% | +290.9% |
| COGT | Buy | COGENT BIOSCIENCES INC | $47,855,000 | +71.8% | 3,207,441 | +3.8% | 1.39% | +59.1% |
| Buy | ARCELLX INC | $46,276,000 | +124.1% | 2,465,405 | +115.9% | 1.34% | +107.6% | |
| VERU | Buy | VERU INC | $44,847,000 | +13.4% | 3,893,000 | +11.2% | 1.30% | +5.1% |
| SGEN | Buy | SEAGEN INC | $43,313,000 | +9.3% | 316,544 | +41.3% | 1.26% | +1.3% |
| TMCI | Buy | TREACE MED CONCEPTS INC | $35,356,000 | +162.0% | 1,601,979 | +70.2% | 1.03% | +142.6% |
| ESTA | Buy | ESTABLISHMENT LABS HLDGS INC | $31,578,000 | +43.1% | 578,253 | +42.5% | 0.92% | +32.6% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $28,523,000 | +91.2% | 336,481 | +86.9% | 0.83% | +77.3% |
| SRPT | New | SAREPTA THERAPEUTICS INC | $27,967,000 | – | 253,000 | +100.0% | 0.81% | – |
| EW | New | EDWARDS LIFESCIENCES CORP | $27,268,000 | – | 330,000 | +100.0% | 0.79% | – |
| ZYME | Buy | ZYMEWORKS INC | $27,060,000 | +23.6% | 4,400,099 | +6.5% | 0.78% | +14.4% |
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $25,034,000 | +122.6% | 1,220,575 | +25.6% | 0.73% | +106.5% |
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $25,025,000 | +72.2% | 366,400 | +14.0% | 0.73% | +59.6% |
| CMAX | Buy | CAREMAX INC | $24,070,000 | +121.0% | 3,394,939 | +13.2% | 0.70% | +105.0% |
| RVNC | Buy | REVANCE THERAPEUTICS INC | $21,834,000 | +176.0% | 808,671 | +41.2% | 0.63% | +155.6% |
| New | CYTEK BIOSCIENCES INC | $18,982,000 | – | 1,289,534 | +100.0% | 0.55% | – | |
| OM | Buy | OUTSET MED INC | $18,616,000 | +25.4% | 1,168,630 | +17.0% | 0.54% | +16.1% |
| RCUS | New | ARCUS BIOSCIENCES INC | $17,435,000 | – | 666,477 | +100.0% | 0.51% | – |
| CRY | Buy | ARTIVION INC | $16,667,000 | -5.0% | 1,204,229 | +29.5% | 0.48% | -12.0% |
| AKRO | New | AKERO THERAPEUTICS INC | $14,642,000 | – | 430,000 | +100.0% | 0.42% | – |
| PRTA | New | PROTHENA CORP PLC | $13,945,000 | – | 230,000 | +100.0% | 0.40% | – |
| AXGN | New | AXOGEN INC | $11,320,000 | – | 949,626 | +100.0% | 0.33% | – |
| LRMR | New | LARIMAR THERAPEUTICS INC | $9,152,000 | – | 2,860,000 | +100.0% | 0.27% | – |
| NVRO | New | NEVRO CORP | $6,990,000 | – | 150,000 | +100.0% | 0.20% | – |
| RVMD | New | REVOLUTION MEDICINES INC | $6,123,000 | – | 310,500 | +100.0% | 0.18% | – |
| NTRA | New | NATERA INC | $5,258,000 | – | 120,000 | +100.0% | 0.15% | – |
| TCDA | New | TRICIDA INCput | $5,240,000 | – | 500,000 | +100.0% | 0.15% | – |
| NARI | New | INARI MED INC | $5,085,000 | – | 70,000 | +100.0% | 0.15% | – |
| CTIC | New | CTI BIOPHARMA CORP | $4,279,000 | – | 735,165 | +100.0% | 0.12% | – |
| ATNX | Buy | ATHENEX INC | $4,178,000 | -24.6% | 15,532,467 | +14.8% | 0.12% | -30.5% |
| PSTX | New | POSEIDA THERAPEUTICS INC | $2,648,000 | – | 750,000 | +100.0% | 0.08% | – |
| RETA | New | REATA PHARMACEUTICALS INCcl a | $2,513,000 | – | 100,000 | +100.0% | 0.07% | – |
| New | MOTUS GI HLDGS INC | $221,000 | – | 90,027 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
About Perceptive Advisors
Perceptive Advisors is a New York-based hedge fund that specializes in healthcare investments. The company was founded in 1999 by Joseph Edelman, who serves as the CEO and Chief Investment Officer. Since its inception, Perceptive Advisors has become one of the most successful healthcare-focused hedge funds in the world, with over $5 billion in assets under management.
The company's investment strategy is based on a deep understanding of the healthcare industry and a focus on identifying promising companies with innovative products and technologies. Perceptive Advisors invests in a wide range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services.
One of the key factors behind Perceptive Advisors' success is its team of experienced professionals. In addition to Joseph Edelman, the company's leadership team includes Adam Stone, the COO, and Jeremy Goldberg, the Chief Scientific Officer. The team also includes a group of highly skilled analysts and researchers who are experts in their respective fields.
Perceptive Advisors has a strong track record of generating high returns for its investors. However, it is important to note that investing in hedge funds carries significant risks, and investors should carefully consider their investment objectives and risk tolerance before investing. As with any investment, it is important to conduct thorough research and seek the advice of a qualified financial advisor before making any investment decisions.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES SHARES | 42 | Q3 2023 | 15.7% |
| AMICUS THERAPEUTICS SHARES | 39 | Q3 2023 | 14.0% |
| ALDEYRA THERAPEUTICS SHARES | 35 | Q3 2023 | 3.3% |
| QUOTIENT TECHNOLOGY INC | 34 | Q3 2022 | 2.7% |
| GLOBAL BLOOD THERAPEUTICS SHARES | 29 | Q3 2022 | 9.3% |
| ADMA BIOLOGICS SHARES | 29 | Q3 2023 | 1.4% |
| RETROPHIN SHARES | 28 | Q3 2020 | 5.5% |
| DBV TECHNOLOGIES SA-SPON ADR | 28 | Q3 2021 | 1.8% |
| VBI VACCINES SHARES | 27 | Q1 2023 | 2.8% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
View Perceptive Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHEMBIO DIAGNOSTICS, INC.Sold out | May 04, 2023 | 0 | 0.0% |
| VBI Vaccines Inc/BC | April 07, 2023 | 43,509,553 | 16.7% |
| Landos Biopharma, Inc. | March 30, 2023 | 14,869,915 | 47.7% |
| REATA PHARMACEUTICALS INC | March 07, 2023 | 2,083,799 | 6.5% |
| AGILE THERAPEUTICS INCSold out | February 14, 2023 | 0 | 0.0% |
| ALBIREO PHARMA, INC. | February 14, 2023 | 1,757,160 | 8.5% |
| BELLUS Health Inc. | February 14, 2023 | 8,891,027 | 7.1% |
| CinCor Pharma, Inc. | February 14, 2023 | 2,576,325 | 5.9% |
| Coherus BioSciences, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| CONCERT PHARMACEUTICALS, INC. | February 14, 2023 | 1,800,000 | 3.6% |
View Perceptive Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-04-17 |
| SC 13D/A | 2024-04-17 |
| 4 | 2024-04-15 |
| SC 13G/A | 2024-04-15 |
| SC 13G | 2024-04-15 |
| SC 13D/A | 2024-04-10 |
| 4 | 2024-04-08 |
| 4 | 2024-04-03 |
| SC 13D/A | 2024-04-03 |
| SC 13D | 2024-03-20 |
View Perceptive Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.